Document:

Exhibit 10.3

 

AMENDED AND RESTATED
FOURTEENTH AMENDMENT TO LEASE

 

Amendment
made this 27TH day of June 2016, amending the Lease dated March 9, 2000 and amended on October 26, 2000, March
12, 2001, April 22, 2002, March 8, 2005, April 5, 2006, January 31, 2007, October 1, 2008, February 19, 2010, March 7, 2011,
March 3, 2012, April 16, 2013 May 5, 2014, December 12, 2014 AND January 5, 2016 (collectively, the “Lease”)

 

	Between	Princeton
    Corporate Plaza, LLC (“Landlord”)
	 	 
	And	Cytosorbents, Inc.,
    f/k/a Medasorb Corporation (“Tenant”)

 

Witnesseth:

 

Whereas the Lease terminated
on May 31, 2016 and;

 

Whereas Tenant desires
Landlord to extend the Term;

 

Now, therefore, in consideration
of the mutual understanding between them and intending to be legally bound, Landlord and Tenant hereby agree to amend the Lease
as follows:

 

		1.	Term. The Term of the Lease
                                         is hereby extended to May 31, 2018 (the “Expiration Date”).

 

		2.	Base
                                         Rent. Effective on June 1, 2016, Base Rent for the remainder of the Term shall be
                                         $22,035.00 per month.

 

		3.	Estimated Operating Expense.
                                         Effective on June 1, 2016, Tenant’s estimated monthly operating expense shall
                                         be $7,022.00 and Tenant’s estimated monthly HVAC maintenance charge shall be $270.00.

 

		4.	Electric and Gas. Effective
                                         on June 1, 2016, Tenant shall pay as Additional Rent for estimated usage the amounts
                                         of $5,825.00 per month for electricity and $1,063.00 per month for gas.

 

		5.	Seventh Expansion Space. Landlord
                                         does hereby lease to Tenant and Tenant does hereby rent from Landlord the following described
                                         premises: approximately 1,420 square feet in Landlord’s Building at 7 Deer Park
                                         Drive, Suite J (the “Seventh Expansion Space”) in the Township of
                                         South Brunswick in the County of Middlesex and State of New Jersey, which space is further
                                         described as the cross-hatched area on the Floor Plan marked Exhibit A-20 attached
                                         hereto and made a part hereof.

 

		6.	Demised Premises. Effective
                                         on August 1, 2016 (the “Seventh Expansion Commencement Date”), the
                                         Seventh Expansion Space shall be included in the Demised Premises and the total area
                                         of the Demised Premises shall be approximately 12,916 square feet.

 

		7.	Use. The Demised Premises
                                         shall be used and occupied only and for no other purpose than office and laboratories
                                         (the “Use”), provided, however, that said Use in the laboratories
                                         shall be strictly limited and subject to the activities set forth in Tenant’s Application
                                         for Nonresidential Use Performance Standards and Tenancy Review submitted to and approved
                                         by the Township of South Brunswick regardless of whether said approval has been received
                                         as of the date of execution of this Lease (the “Tenancy Review”).

 

		8.	Base Rent. Effective
                                         on the Seventh Expansion Commencement Date, Tenant’s monthly Base Rent for the
                                         remainder of the Term shall be $24,756.00.

 

		9.	Security. Tenant has this
                                         day deposited with Landlord the sum of $20,342.00 as additional security thereby increasing
                                         Tenant’s total security deposit to $81,370.00.

 

		10.	Tenant’s Proportionate
                                         Share. Effective on the Seventh Expansion Commencement Date, Tenant’s Proportionate
                                         Share for the remainder of the Term shall be 24.58%.

 

		11.	Estimated Operating Expense.
                                         Effective on the Seventh Expansion Commencement Date, Tenant’s estimated monthly
                                         Operating Expense shall be $7,890.00 and Tenant’s monthly HVAC maintenance charge
                                         shall be $300.00.

 

    	 	1	 

     

    

 

		12.	Electric
                                         and Gas. Effective on the Seventh Expansion Commencement Date, Tenant shall pay as
                                         Additional Rent for estimated usage the amounts of $6,544.00 per month for electricity
                                         and $1,195.00 per month for gas.

 

		13.	Acceptance
                                         and Workletter.

 

		a.	Landlord shall complete at its
                                         own expense and in a good and workmanlike manner all of the alterations to the Seventh
                                         Expansion Space set forth on Exhibit B-14 (“Landlord’s Work”)
                                         attached hereto and made a part hereof. Tenant acknowledges that it has inspected and
                                         examined the Seventh Expansion Space and, except as set forth in Exhibit B-14, has
                                         entered into this Amendment without any representations on the part of Landlord, its
                                         agents or representatives as to the condition thereof, and, except as set forth in Exhibit
                                         B-14, is leasing and accepting the Seventh Expansion Space “as-is” and
                                         “where-is”. No representations or promises, except as specified herein, have
                                         been made by or on behalf of Landlord, its agents, employees or representatives, or by
                                         any real estate broker, prior to or at the execution of this Amendment, and Landlord
                                         is not bound by, and Tenant will make no claim on account of, any representation, promise
                                         or assurance, expressed or implied, with respect to conditions, repairs, improvements,
                                         services, accommodations, concessions or any other matter, other than as contained herein.

 

		b.	Landlord shall at Tenant’s
                                         sole cost and expense complete in a good and workmanlike manner and in compliance with
                                         all government rules and regulations all of the alterations set forth on Exhibit B-15
                                         (“Tenant’s Work”) attached hereto and made a part hereof.

 

		14.	Commencement Date.

 

		1)	The Commencement Date shall be
                                         earlier or later than the date set forth at the beginning of this Lease under the following
                                         circumstances:

 

		a)	The Lease will not commence until
                                         the work listed in Exhibit B-14, to be performed by Landlord, is substantially
                                         completed, unless Tenant chooses to occupy the Demised Premises, or any part thereof,
                                         prior to substantial completion, in which case the Commencement Date shall be the date
                                         of said occupancy by Tenant.

 

		b)	Except
                                         as provided in the preceding paragraph, the Commencement Date will not be altered if
                                         the work listed in Exhibit B-14, to be performed by Landlord, is not substantially
                                         completed due to (i) changes requested by Tenant to Exhibit B-14 after this Lease
                                         was executed or (ii) the failure of Tenant to promptly provide Landlord with any information
                                         necessary for the timely completion of the work listed in Exhibit B-14 or (iii)
                                         the failure of Tenant to cooperate with Landlord in completion of the work listed in
                                         Exhibit
                                         B-14 to such an extent as to cause the delay.

 

		2)	Substantial
                                         completion shall be deemed to have occurred even though (i) minor details of Landlord’s
                                         work remain to be done, provided such details do not materially interfere with the Tenant’s
                                         occupancy of the Demised Premises, or (ii) any work or installation other than Landlord’s
                                         work being performed by Tenant itself has not been completed.

 

		3)	Landlord
                                         shall not be liable for failure to give possession of the Demised Premises, or any part
                                         thereof, upon the Commencement Date by reason of the fact that the Demised Premises,
                                         or any part thereof, are not ready for occupancy, or due to a prior tenant holding over
                                         in the Demised Premises or due to any other person being in possession of the Demised
                                         Premises or for any other reason.

 

		15.	Renewal Option.

 

		1)	Tenant has the option to renew
                                         for one ( 1) successive one ( 1) year term upon six (6) months written notice to Landlord
                                         prior to the expiration of the term of this Lease, time being of the essence; provided,
                                         however, that Tenant is not in default under any of the terms and conditions of this
                                         Lease and no event has occurred which with the giving of notice, passage of time, or
                                         both, would constitute an event of default on the date (i) this option is exercised and
                                         (ii) the renewal term commences. Base Rent for the renewal term shall be increased by
                                         the greater of five percent (5%) or the increases (if any) in the Consumer Price Index
                                         as published by the U.S. Department of Labor (“CPI”). Base
                                         Rent for the renewal term shall be determined (and shall be effective for the entire
                                         then operative lease years in the renewal term) by multiplying the annualized Base Rent
                                         in the last month of the prior term by the greater of a) five percent (5%) or b) a fraction,
                                         the numerator of which fraction shall be the CPI figure for the month which is two (2)
                                         months prior to the month in which the Commencement Date occurred (the “CPI
                                         Month”) and the denominator of which fraction shall be the figure published
                                         for the corresponding month in the initial lease year for the first renewal and for subsequent
                                         renewals, the month used for the numerator in the preceding renewal period. The CPI used
                                         shall be the All Urban Consumers (CPI-U), U.S. City Average.

 

    	 	2	 

     

    

 

		3)	Should the CPI cease to be published,
                                         then the closest similar published index by an agency of the U.S. Government shall be
                                         substituted. Should there be no such substitute, the parties hereto shall, under the
                                         rules of the American Arbitration Association, agree to a substitute formula or source,
                                         designed to accomplish the same original purpose of this provision.

 

		16.	Tenant’s Statement of
                                         Estoppel in Favor of Landlord. Tenant hereby confirms that to the best of its knowledge,
                                         after due inquiry and consideration:

 

a.   Tenant
does not have any pending or potential causes of action, suits, liabilities, debts, damages, controversies, agreements, trespasses,
judgments, executions, demands and claims of any nature whatsoever, whether in law or in equity, against Landlord, its predecessors.
successors and assigns, its parents, subsidiaries, officers, directors, shareholders, employees, agents and attorneys, any affiliated
corporations, their officers, directors, shareholders and employees, by reason of any matter or cause whatsoever related to or
arising from the Lease, or any other matter which has arisen prior to the date of execution of this Amendment.

 

b.
   The Lease
is in full force and effect and there are no defaults thereunder by Tenant (or to Tenant’s knowledge, by Landlord), nor
are there any conditions which with the passage of time or giving of notice or both would become a default under the Lease.

 

c.
   The Lease
is the only agreement between Tenant and the Landlord affecting the Premises, and the Lease has not been assigned, amended, modified,
changed, altered or supplemented, except as expressly specified herein. Tenant has no notice or knowledge of any person claiming
rights as landlord or as tenant under the Lease other than Landlord and Tenant respectively.

 

d.
   Tenant
is in full and complete possession of the Premises pursuant to the terms of the Lease. There are no options by Tenant or rights
to expand the Premises provided for in the Lease, except as may be expressly provided in the Lease.

 

e.
   All duties
of an inducement nature and all inducement clauses have been fulfilled by Landlord in all respects, including any allowance and
rent and other financial concessions.

 

f.
   Tenant
has not, at the Premises or within the building, generated, stored, handled or otherwise dealt with any hazardous or toxic waste
or material, radioactive materials, or other contaminants, the removal of which is required or the maintenance of which is prohibited,
regulated or penalized by an local, state or federal agency, authority or government unit except as expressly permitted in the
Lease.

 

g.
   No petition,
suit or proceeding involving Tenant’s bankruptcy, insolvency, reorganization, receivership, or general assignment for the
benefit of creditors is currently pending or contemplated.

 

		17.	Release in Favor of Landlord.
                                         Tenant hereby releases and forever discharges Landlord, its predecessors, successors
                                         and assigns, its parents, subsidiaries, officers, directors, shareholders, employees,
                                         agents and attorneys, any affiliated corporations, their officers, directors, shareholders
                                         and employees, from any and all causes of action, suits, liabilities, debts, damages,
                                         controversies, agreements, trespasses, judgments, executions, demands and claims of any
                                         nature whatsoever, whether in law or in equity, whether known or unknown, and any and
                                         all rights, duties, liabilities and obligations, whether presently enforceable or enforceable
                                         in the future, by reason of any matter or cause whatsoever from the beginning of time
                                         to the date of its execution of this Amendment, related to or arising from the Lease.

 

		18.	Tenant’s Representations.
                                         Tenant represents and warrants that Tenant and the person(s) executing and delivering
                                         this Amendment on Tenant’s behalf each represent and warrant that such person is
                                         duly authorized to so act; that Tenant is duly organized, is qualified to do business
                                         in the State of New Jersey, is in good standing under the laws of the state of its organization
                                         and the laws of the State of New Jersey, and has the power and authority to enter into
                                         this Lease; and that all action required to authorize Tenant and such person to enter
                                         into this Lease has been duly taken.

 

		19.	Lease Amendment Submission.
                                         Tenant has executed this Amendment upon the understanding that this Lease shall not
                                         in any way bind Landlord until such time as the same has been approved and executed by
                                         Landlord and a counterpart delivered to or received by Tenant.

 

		20.	Entire Lease. This Amendment
                                         is made a part of the Lease and where a conflict exits between any provision in the Lease
                                         and the provisions of this Amendment, this Amendment shall govern. Except as specifically
                                         amended herein, all of the terms and conditions of the Lease shall continue with full
                                         force and effect.

 

    	 	3	 

     

    

 

IN WITNESS
WHEREOF, the parties hereto have hereunto set their hands and seals, or caused these presents to be signed by their
proper corporate officers or other duly authorized representatives and their proper corporate seal (if applicable) to be hereto
affixed, as of the day and year first above written.

 

	WITNESS:	 	LANDLORD
	 	 	Princeton Corporate Plaza, L.L.C.
	 	 	By:	Princeton Corporate Management Corp.,

 Managing
    Member

 

	/s/ Pamela R. Kent	 	By:	/s/
    Teresa Ryan Kent
	 	 	Name:
    Teresa Ryan Kent
	8/5/16	 	Title:
    Treasurer
	Date	 	 
	 	 	 
	WITNESS:	 	TENANT
	 	 	Cytosorbents,
    Inc.
	 	 	 
	/s/ Kathleen P. Bloch 	 	By:	/s/
    Phillip Chan
	 	 	Name:
    Phillip Chan
	8-4-2016	 	Title:
    CEO
	Date	 	 

 

    	 	4	 

     

    

 

EXHIBIT
A-20

 

Seventh Expansion Space

 

  

    	 	5	 

     

    

 

EXHIBIT A-21

 

Workletter Floor Plan

 

 

 

    	 	6	 

     

    

 

EXHIBIT A-22

 

Workletter Outlet Plan

 

 

 

    	 	7	 

     

    

 

EXHIBIT
A-23

 

Workletter Ceiling Plan

 

 

 

    	 	8	 

     

    

 

EXHIBIT B-14

 

Description of Landlord’s Work

 

All Special Requirements of Tenant that are not included in
this Exhibit shall be at the sole cost and expense of Tenant.

 

		1.	FLOORING:

	Office
    Area:	 	Existing hardwood.
	Laboratory:	 	New epoxy paint.
	Corridor Area:	 	New VCT from bathrooms to front executive offices.
    Replace black vinyl base with gray vinyl base.

 

		2.	PARTITIONS:

	Office
    Area:	 	As shown on the outlined
    area of Exhibit A-21 Floor Plan except for the items set forth in Exhibit B-15 “Description of Tenant’s Work”
	Laboratory:	 	As shown on Exhibit A-21 Floor Plan except for
    the items set forth in Exhibit B-15 “Description of Tenant’s Work” 
	Old Packing Room:	 	Remove partition wall.

 

		3.	ELECTRICAL:

	Office
    Area:	 	As shown on the outlined
    area of Exhibit A-22 Outlet Plan except for the items set forth in Exhibit B-15 “Description of Tenant’s Work”
	Laboratory:	 	As shown on the outlined area of Exhibit A-22
    Outlet Plan except for the items set forth in Exhibit B-15 “Description of Tenant’s Work”

All Special Electric by Tenant. All outlets are 110v
unless otherwise specified on Exhibit A-22.

 

		4.	LIGHTING:

	Office
    Area:	 	As shown on the outlined
    area of Exhibit A-23 Ceiling Plan except for the items set forth in Exhibit B-15 “Description of Tenant’s Work”
	Laboratory:	 	As shown on the outlined area of Exhibit A-23
    Ceiling Plan except for the items set forth in Exhibit B-15 “Description of Tenant’s Work”

 

		5.	CEILINGS:

	Office
    Area:	 	As shown on the outlined
    area of Exhibit A-23 Ceiling Plan except for the items set forth in Exhibit B-15 “Description of Tenant’s Work”
	Laboratory:	 	As shown on the outlined area of Exhibit A-23
    Ceiling Plan except for the items set forth in Exhibit B-15 “Description of Tenant’s Work” 
	Corridor Area, Hall
    & Bathrooms:	 	Replace damaged ceiling tiles.

 

		6.	WALL FINISH:

	Office Area:	 	Painted, white.
	Laboratory:	 	Painted, white.
	Corridor Area:	 	Touch up patching and painting to
    corridor walls & trim. Paint door trims gray to match cove base. Install corner guards. Clean up corridor doors with clear
    coat. Install kick plate on Mechanical Room Door 013.
	Conference
    Room:	 	Touch up painting conference
    room.	

 

		7.	INTERIOR DOORS:

	Office
    Area:	 	As shown on the outlined
    area of Exhibit A-21 Floor Plan except for the items set forth in Exhibit B-15 “Description of Tenant’s Work”
	Laboratory:	 	As shown on the outlined area of Exhibit A-21
    Floor Plan except for the items set forth in Exhibit B-15 “Description of Tenant’s Work”
	Corridor Area:	 	Relocate break-room door to hallway wall. Close
    up existing door area.

 

		8.	PLUMBING:

	Corridor Area:	 	Cold water connections to
    fume hoods.
		 	Relocate existing safety eyewash from rear corridor
    to Quality Control lab, relocate thermostat.

 

	9.	HEATING & AIR CONDITIONING:	Cooling 78 degrees at 95 degrees.
	 	 	Heating 68 degrees at 0 degrees.

 

	10.	FIRE EXTINGUISHERS:	As per Township code.

 

	11.	SPRINKLERS:	As per Township code.

 

	12.	LABORATORY EQUIPMENT & FURNISHINGS: Three (3) fume hoods, cabinets and benches per Exhibit A-21 Floor Plan. Remove old security system components, relocate benches and cabinets from old packing room to new packing room.

 

	13.	OTHER:	Remove bug zappers in
    foyer. Patch and paint. Patch and paint where tenant has pill sign removed. Hard prune interior tree and repair ceiling leak
    in foyer. Clean up general landscaping at entrance, including removing dead plants, tree and stump.

 

    	 	9	 

     

    

 

EXHIBIT B-15

 

Description of Tenant’s Work

 

Fit-out Costs by Tenant:

 

All special requirements not included in Exhibit B-14 will
be at Tenant cost.

 

The following are included in the cost specified in Paragraph
9 of this Amendment:

 

	ITEM	 	DESCRIPTION	 	COST
	Data & Telecommunications	 	Equipment & Installation	 	By Tenant
	 	 	 	 	 
	Tenant Equipment	 	Mechanical Connections	 	TBD
	 	 	 	 	 
	Signage	 	Interior and exterior Tenant signs	 	By Tenant
	 	 	 	 	 
	Polymer lab floor	 	Repair and epoxy paint floor	 	50% By Tenant
	 	 	 	 	 
	Polymer lab door	 	Install door from Polymer lab to Expansion 7
    Suite J lab	 	By Tenant

 

    	 	10rgnx-ex1036_117.htm

 

EXHIBIT 10.36

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

University of Pennsylvania

Third Amendment to License Agreement

This Third Amendment to License Agreement (this “Third Amendment”) effective as of  April 29, 2016 (this “Third Amendment Effective Date”), is made by and between The Trustees of the University of Pennsylvania (“Penn”) and REGENXBIO Inc. (“Company”) (collectively, the “Parties”) and amends the License Agreement between the Parties, which was effective as of February 24, 2009, as subsequently amended by a First Amendment dated March 6, 2009 and a Second Amendment dated September 9, 2014 (the “License Agreement”).  All capitalized terms used but not defined herein shall have the meaning set forth in the License Agreement.

BACKGROUND

WHEREAS, the Parties are simultaneously entering into a Clinical Trial Research Agreement relating to evaluation of the safety of AAV8.TBG.hLDLR, a replication deficient recombinant adeno-associated virus vector 8 (AAV8) expressing human Low Density Lipoprotein receptor (LDLR) from liver-specific thyroxine-binding globulin (TBG) promoter, (the “Study Drug”) in certain patients with Homozygous Familial Hypercholesterolemia (HoFH) in a Phase 1/2 clinical trial as set forth in the Clinical Trial Research Agreement (the “Study”); 

WHEREAS, Company wishes to license, and Penn agrees to provide to Company with, a license to data, results and other information generated in connection with the Study in the furtherance of Company’s commercialization objectives, including Company’s intention to seek marketing authorization from the FDA and other regulatory authorities for the Study Drug and the treatment of patients with HoFH; and

WHEREAS, the Parties desire that the License Agreement be amended as set forth below in order to amend the license grants to include within the scope of the License Agreement certain rights to data, results and other information generated from the Study;

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the Parties, intending to be bound, hereby mutually agree to the following:

1. The following definitions in Section 1.2 of the License Agreement shall be amended and restated in their entirety as follows:

“Background Know-How” means all (i) Know-How that (a) was developed by Dr. Wilson, or other Penn researchers working under his direct supervision, at Penn, and (b) is related to the adeno associated virus technology platform discovered by Dr. Wilson at Penn prior to September 9, 2014 or is related to the adeno associated virus technology platform discovered by Dr. Wilson at Penn during the performance of a Company sponsored research program after September 9, 2014, and (c) is owned by Penn, (d) is necessary or useful for the practice of the Patent Rights in connection with the manufacture, use, sale, importation and/or other exploitation of the Licensed Products or the practice of the Licensed Processes in the Territory in the Field of Use, including, without, limitation, any Know-How necessary for the Company to manufacture or have manufactured the materials produced by the Penn Vector Core or Dr. Wilson's lab at Penn; and (ii) Penn Study Data.

“Field of Use” means any and all fields of use, except with respect to (i) the Patent Rights listed in Exhibit A, Part 2 and all related Know-How and data, for which the Field of Use is limited to viral vector mediated gene therapy, and (ii) the Penn Study Data, for which the Field of Use is limited to the treatment of familial hypercholesterolemia (FH).

1

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

“Licensed Products” means any products that are made, made for, used, imported, offered for sale or sold by or for Company or its Affiliates or sublicensees and that either (i) in the absence of this Agreement, would infringe or misappropriate the Licensed IP, or any claim thereof whether or not the claim is issued or pending, or (ii) use, or are manufactured using, a Licensed Process, or (iii) rely on the Penn Study Data in connection with the regulatory approval of such a product for treating FH, or (iv) are supported by Penn Study Data that corresponds to and/or supports the patentability of such product or its use in the field.  Licensed Products include Licensed Pharmaceutical Products and Licensed Reagents. 

2. The following definitions shall be added to Section 1.2 of the License Agreement:

“Clinical Research” means all those tests, studies and other activities described in the Protocol or required in order to obtain the information set out in the Protocol together with such other activities as may be agreed on to be undertaken by Penn and Company in accordance with Clinical Trial Research Agreement between Penn and the Company dated April 29, 2016 (the “HoFH CTRA”).

“Penn Study Data” means all data and information that are generated in the performance of the Clinical Research during the term of this Agreement.

“Protocol” means a description of the research to be undertaken by Penn and/or Company as set forth in Exhibit A of the HoFH CTRA, as may be amended pursuant to Section 20 of the HoFH CTRA.

3. The following definitions in Section 3.5 of the License Agreement shall be amended and restated in their entirety as follows:

“Royalty Term” means, on a product-by-product, country-by-country basis with respect to Licensed Products in a Field of Use other than for treating FH, the period commencing on the date of the first Sale of such Licensed Product and ending on the date the Licensed Product ceases to be covered by a valid claim (issued or pending) of the Patent Rights.  With respect to Licensed Products for treating FH, “Royalty Term” means, on a product-by-product, country-by-country basis, the period commencing on date of the first Sale of such Licensed Product for treating FH and ending on the later of: (i) the date the Licensed Product for treating FH ceases to be infringed or covered by a valid claim (issued or pending) of the Patent Rights, and (ii) **** following the first Sale of such Licensed Product for treating FH.

4. Exhibit A of the License Agreement is hereby amended and restated in its entirety by Exhibit A-1 to this Third Amendment to add the additional Patent Rights and Know-How.

5. This Third Amendment amends the terms of the License Agreement and is deemed incorporated into, and governed by all other terms of, the License Agreement.  To the extent that the License Agreement is explicitly amended by this Third Amendment, the terms of this Third Amendment will control where the terms of the License Agreement are contrary to or conflict with the terms of this Third Amendment.  All other terms and conditions of the License Agreement not explicitly amended by this Third Amendment shall remain in full force and effect.  The License Agreement, as previously amended, shall, together with this Third Amendment, be read and construed as a single instrument.

6. Signatures on this Third Amendment may be communicated by facsimile or e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by facsimile or e-mail transmission, which signatures shall be deemed originals.  If executed in counterparts, the Third Amendment shall be effective as if simultaneously executed.

[Intentionally left blank]

 

 

 

2

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this Third Amendment to be executed by their duly authorized representatives.

 

	
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

	
 
	
 
	
 

	
By:
	
 
	
/s/ John S. Swartley, PhD
	
 

	
Name:
	
 
	
John S. Swartley, PhD

	
Title:
	
 
	
Associate Vice Provost for Research and Executive Director, PCI

	
Date:
	
 
	
June 2, 2016
	
 

	
 
	
 
	
 

	
REGENXBIO INC.

	
 
	
 
	
 

	
By:
	
 
	
/s/ Kenneth T. Mills
	
 

	
Name:
	
 
	
Kenneth T. Mills

	
Title:
	
 
	
President and CEO

	
Date:
	
 
	
June 6, 2016
	
 

 

 

 

3

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

Exhibit A-1

Patents and Patent Applications in the Patent Rights

Part 1; No Field of Use Limitation

 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

4

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****.1
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

5

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

6

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

7

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
330122
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
****

8

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

9

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

10

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****
	
****
	
****
	
****
	
****
	
****

	
****
	
****

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

11

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

 

	
Docket V5085
	
 
	
Combinational method to generate novel and/or hybrid coding sequences within the defined domains

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

 

	
Docket V5131
	
A domain of the adeno-associated virus stereotype 6 capsid that confers transduction of conducting airway epithelium

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
****
	
****
	
****
	
****
	
****
	
****

 

	
Docket X5836
	
The receptor for AAV9 and its modification in vivo to improve lung gene therapy

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

 

	
Docket Z6622
	
Compositions and Methods for Treatingment of MPSI1

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
 
	
 
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

12

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

Exhibit A, Part 2- 

Field of Use limited to viral vector mediated delivery of gene therapy product.

 

	
Docket 14-7025
	
Improved AAV-LDLR for treating human disease

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

 

	
Docket 14-7037
	
AAV OTC for treating human disease

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

 

	
Docket 16-7717
	
Methods and compositions for treating lowering cholesterol

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

	
****
	
 
	
****
	
****
	
****
	
****
	
 

 

	
Docket 15-7487
	
Compositions and Methods for Treating MPSI

	
Serial No
	
Patent No
	
App Type
	
File Date
	
Status
	
Country
	
Issue Date

	
****
	
 
	
****
	
****
	
****
	
****
	
 

Penn / Wilson Lab Know-How for the Familial Hypercholesterolemia and Onithine 

Transcarbamylase Deficiency (OTC) Programs

FH Know-How (associated with ****)

****

 

 

 

13

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED

Final Execution Copy

 

OTC Know-How (associated with ****)

**** 

14

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]